Stress conditions triggering mucoid morphotype variation in burkholderia species and effect on virulence in galleria mellonella and biofilm formation in vitro

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Silva, Inês N ^a   Tavares, Andreia C ^a   Ferreira, Ana S ^a   Moreira, Leonilde M ^a  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; BACTERIAL DNA; CEFTAZIDIME; CIPROFLOXACIN; EXOPOLYSACCHARIDE; IMIPENEM; IRON; PIPERACILLIN PLUS TAZOBACTAM; SIDEROPHORE; TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BIOFILM; BURKHOLDERIA; BURKHOLDERIA MULTIVORANS; CONTROLLED STUDY; GALLERIA MELLONELLA; MORPHOTYPE; NONHUMAN; OSMOTIC STRESS; OXIDATIVE STRESS; SURVIVAL RATE;

ANIMALS; BIOFILMS; BURKHOLDERIA; BURKHOLDERIA INFECTIONS; MOTHS; OXIDATIVE STRESS; STRESS, PHYSIOLOGICAL; VIRULENCE;

EID: 84892729520     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082522     Document Type: Article

References (44)

1. Harrison F (2007) Microbial ecology of the cystic fibrosis lung. Microbiology 153: 917-923.
2. Mahenthiralingam E, Urban TA, Goldberg JB (2005) The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 3: 144-156.
3. Döring G, Parameswaran IG, Murphy TF (2011) Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease. FEMS Microbiol Rev 35: 124-146.
4. Lyczak JB, Cannon CL, Pier GB (2002) Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15: 194-222.
5. Hogardt M, Heesemann J (2010) Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int J Med Microbiol 300: 557-562.
6. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, et al. (2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 103: 8487-8492.
7. Ciofu O, Lee B, Johannesson M, Hermansen NO, Meyer P, et al. (2008) Investigation of the algT operon sequence in mucoid and non-mucoid Pseudomonas aeruginosa isolates from 115 Scandinavian patients with cystic fibrosis and in 88 in vitro non-mucoid revertants. Microbiology 154: 103-113.
8. Speert DP, Farmer SW, Campbell ME, Musser JM, Selander RK, et al. (1990) Conversion of Pseudomonas aeruginosa to the phenotype characteristic of strains from patients with cystic fibrosis. J Clin Microbiol 28: 188-194.
9. Tavares IM, Leitão JH, Fialho AM, Sá-Correia I (1999) Pattern of changes in the activity of enzymes of GDP-D-mannuronic acid synthesis and in the level of transcription of algA, algC and algD genes accompanying the loss and emergence of mucoidy in Pseudomonas aeruginosa. Res Microbiol 150: 105-116.
10. Terry JM, Pina SE, Mattingly SJ (1991) Environmental conditions which influence mucoid conversion Pseudomonas aeruginosa PAO1. Infect Immun 59: 471-477.
11. Boles BR, Thoendel M, Singh PK (2004) Self-generated diversity produces "insurance effects" in biofilm communities. Proc Natl Acad Sci 101: 16630-16635.
12. Zlosnik JE, Hird TJ, Fraenkel MC, Moreira LM, Henry DA, et al. (2008) Differential mucoid exopolysaccharide production by members of the Burkholderia cepacia complex. J Clin Microbiol 46: 1470-1473.
13. Silva IN, Ferreira AS, Becker JD, Zlosnik JEA, Speert DP, et al. (2011) Mucoid morphotype variation of Burkholderia multivorans during chronic cystic fibrosis lung infection is correlated with changes in metabolism, motility, biofilm formation and virulence. Microbiology 157: 3124-3137.
14. Zlosnik JE, Speert DP (2010) The role of mucoidy in virulence of bacteria from the Burkholderia cepacia complex: a systematic proteomic and transcriptomic analysis. J Infect Dis 202: 770-781.
15. Conway BA, Chu KK, Bylund J, Altman E, Speert DP (2004) Production of exopolysaccharide by Burkholderia cenocepacia results in altered cell-surface interactions and altered bacterial clearance in mice. J Infect Dis 190: 957-966.
16. Zlosnik JE, Costa PS, Brant R, Mori PY, Hird TJ, et al. (2011) Mucoid and nonmucoid Burkholderia cepacia complex bacteria in cystic fibrosis infections. Am J Respir Crit Care Med 183: 67-72.
17. Moreira LM, Da Costa MS, Sá-Correia I (1997) Comparative genomic analysis of isolates belonging to the six species of the genus Thermus using pulsed-field gel electrophoresis and ribotyping. Arch Microbiol 168: 92-101.
18. Van Acker H, Van Snick E, Nelis HJ, Coenye T (2010) In vitro activity of temocillin against planktonic and sessile Burkholderia cepacia complex bacteria. J Cyst Fibros9: 450-454.
19. Ferreira AS, Leitão JH, Sousa SA, Cosme AM, Sá-Correia I, et al. (2007) Functional analysis of Burkholderia cepacia genes bceD and bceF, encoding a phosphotyrosine phosphatase and a tyrosine autokinase, respectively: role in exopolysaccharide biosynthesis and biofilm formation. Appl Environ Microbiol 73: 524-534.
20. Miller JH (1972) Experiments in Molecular Genetics. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
21. Bauer AW, Kirby WM, Sherris JC, Turck M (1966) Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 45: 493-496.
22. Schwyn B, Neilands JB (1987) Universal chemical assay for the detection and determination of siderophores. Anal Biochem 160: 47-56.
23. Seed KD, Dennis JJ (2008) Development of Galleria mellonella as an alternative infection model for the Burkholderia cepacia complex. Infect Immun 76: 1267-1275.
24. Drevinek P, Baldwin A, Lindenburg L, Joshi LT, Marchbank A, et al. (2010) Oxidative stress of Burkholderia cenocepacia induces insertion sequence-mediated genomic rearrangements that interfere with macrorestriction-based genotyping. J Clin Microbiol 48: 34-40.
25. Govan JR, Deretic V (1996) Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia . Microbiol Rev 60: 539-574.
26. Vial L, Groleau M-C, Lamarche MG, Filion G, Castonguay-Vanier J, et al. (2010) Phase variation has a role in Burkholderia ambifaria niche adaptation. ISME J 4: 49-60.
27. Chantratita N, Wuthiekanun V, Boonbumrung K, Tiyawisutsri R, Vesaratchavest M, et al. (2007) Biological relevance of colony morphology and phenotypic switching by Burkholderia pseudomallei. J Bacteriol 189: 807-817.
28. Tandhavanant S, Thanwisai A, Limmathurotsakul D, Korbsrisate S, Day NP, et al. (2010) Effect of colony morphology variation of Burkholderia pseudomallei on intracellular survival and resistance to antimicrobial environments in human macrophages in vitro. BMC Microbiol 10: 303.
29. Sousa SA, Ulrich M, Bragonzi A, Burke M, Worlitzsch D, et al. (2007) Virulence of Burkholderia cepacia complex strains in gp91phox2/2 mice. Cell Microbiol 9: 2817-2825.
30. Bylund J, Burgess LA, Cescutti P, Ernst RK, Speert DP (2006) Exopolysaccharides from Burkholderia cenocepacia inhibit neutrophil chemotaxis and scavenge reactive oxygen species. J Biol Chem 281: 2526-2532.
31. Ferreira A, Silva I, Oliveira V, Cunha R, Moreira L (2011) Insights into the role of extracellular polysaccharides in Burkholderia adaptation to different environments. Front Cell Infect Microbiol 1: 00016.
32. Chung JW, Altman E, Beveridge TJ, Speert DP (2003) Colonial morphology of Burkholderia cepacia complex genomovar III: implications in exopolysaccharide production, pilus expression, and persistence in the mouse. Infect Immun 71: 904-909.
33. Vandamme P, Holmes B, Vancanneyt M, Coenye T, Hoste B, et al. (1997) Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 47: 1188-1200.
34. Richau JA, Leitão JH, Correia M, Lito L, Salgado MJ, et al. (2000) Molecular typing and exopolysaccharide biosynthesis of Burkholderia cepacia isolates from a Portuguese cystic fibrosis center. J Clin Microbiol 38: 1651-1655.
35. Stanier RY, Palleroni NJ, Doudoroff M (1966) The aerobic pseudomonads: a taxonomic study. J Gen Microbiol 43: 159-271.
36. Glass S, Govan JR (1986) Pseudomonas cepacia - fatal pulmonary infection in a patient with cystic fibrosis. J Infect 13: 157-158.
37. Coenye T, Schouls LM, Govan JR, Kersters K, Vandamme P (1999) Identification of Burkholderia species and genomovars from cystic fibrosis patients by AFLP fingerprinting. Int J Syst Bacteriol 49: 1657-1666.
38. Van Laer F, Raes D, Vandamme P, Lammens C, Sion JP, et al. (1998) An outbreak of Burkholderia cepacia with septicemia on a cardiology ward. Infect Control Hosp Epidemiol 19: 112-113.
39. Larsen GY, Stull TL, Burns JL (1993) Marked phenotypic variability in Pseudomonas cepacia isolated from a patient with cystic fibrosis. J Clin Microbiol 31: 788-792.
40. Coenye T, Mahenthiralingam E, Henry D, LiPuma JJ, Laevens S, et al. (2001) Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. Int J Syst Evol Microbiol 51: 1481-1490.
41. Coenye T, Vandamme P, LiPuma JJ, Govan JR, Mahenthiralingam E (2003) Updated version of the Burkholderia cepacia complex experimental strain panel. J Clin Microbiol 41: 2797-2798.
42. Vandamme P, Goris J, Chen WM, De Vos P, Willems A (2002) Burkholderia tuberum sp. nov. and Burkholderia phymatum sp. nov., nodulate the roots of tropical legumes. Syst Appl Microbiol 25: 507-512.
43. Goris J, De Vos P, Caballero-Mellado J, Park J, Falsen E, et al. (2004) Classification of the biphenyl- and polychlorinated biphenyl-degrading strain LB400T and relatives as Burkholderia xenovorans sp. nov. Int J Syst Evol Microbiol 54: 1677-1681.
44. Ferreira AS, Leitão JH, Silva IN, Pinheiro PF, Sousa SA, et al. (2010) Distribution of cepacian biosynthesis genes among environmental and clinical Burkholderia strains and role of cepacian exopolysaccharide in resistance to stress conditions. Appl Environ Microbiol 76: 441-450.